Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation. Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...